Compare · IMCR vs NXTC
IMCR vs NXTC
Side-by-side comparison of Immunocore Holdings plc (IMCR) and NextCure Inc. (NXTC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. IMCR focuses on Biotechnology: Biological Products (No Diagnostic Substances), while NXTC focuses on Biotechnology: Pharmaceutical Preparations.
- IMCR is the larger of the two at $1.44B, about 46.8x NXTC ($30.7M).
- NXTC has been more active in the news (13 items in the past 4 weeks vs 7 for IMCR).
- IMCR has more recent analyst coverage (25 ratings vs 4 for NXTC).
- Company
- Immunocore Holdings plc
- NextCure Inc.
- Price
- -
- -
- Market cap
- $1.44B
- $30.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2019
- News (4w)
- 7
- 13
- Recent ratings
- 25
- 4
Immunocore Holdings plc
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
NextCure Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; and NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. NextCure, Inc. has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Latest IMCR
- SEC Form SCHEDULE 13G filed by Immunocore Holdings plc
- Immunocore to present at upcoming investor conferences
- Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
- SEC Form 10-Q filed by Immunocore Holdings plc
- Immunocore Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Immunocore reports third quarter financial results and provides a business update
- Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
- Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
- Amendment: SEC Form SCHEDULE 13G/A filed by Immunocore Holdings plc
- Immunocore Holdings plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest NXTC
- Amendment: SEC Form SCHEDULE 13G/A filed by NextCure Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by NextCure Inc.
- Large owner Adar1 Capital Management, Llc bought $62,897 worth of shares (12,333 units at $5.10) (SEC Form 4)
- SEC Form 10-Q filed by NextCure Inc.
- NextCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results
- Large owner Adar1 Capital Management, Llc bought $23,899 worth of shares (4,686 units at $5.10) (SEC Form 4)
- SEC Form EFFECT filed by NextCure Inc.
- SEC Form 424B3 filed by NextCure Inc.
- Amendment: SEC Form S-4/A filed by NextCure Inc.